Pembrolizumab (pembro) plus chemotherapy as front-line therapy for advanced NSCLC: KEYNOTE-021 cohorts A-C.

被引：63

作者：

Gadgeel, Shirish M.

Stevenson, James

Langer, Corey J.

Gandhi, Leena

Borghaei, Hossein

Patnaik, Amita

Villaruz, Liza Cosca

Gubens, Matthew A.

Hauke, Ralph J.

Yang, James Chih-Hsin

Sequist, Lecia V.

Bachman, Robert D.

Ge, Joy Yang

Raftopoulos, Harry

Papadimitrakopoulou, Vassiliki

机构：

[1] Karmanos Canc Inst, Detroit, MI USA

[2] Cleveland Clin Fdn, 9500 Euclid Ave, Cleveland, OH 44195 USA

[3] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA

[4] Dana Farber Canc Inst, Boston, MA 02115 USA

[5] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[6] South Texas Accelerated Res Theraput, San Antonio, TX USA

[7] Univ Pittsburgh, Canc Inst, Pittsburgh, PA USA

[8] Univ Calif San Francisco, San Francisco, CA 94143 USA

[9] Nebraska Canc Specialists, Omaha, NE USA

[10] Natl Taiwan Univ Hosp, Taipei, Taiwan

[11] Natl Taiwan Univ, Canc Ctr, Taipei, Taiwan

[12] Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA

[13] Harvard Med Sch, Boston, MA 02115 USA

[14] Merck & Co Inc, Kenilworth, NJ USA

[15] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

关键词：

D O I：

10.1200/JCO.2016.34.15_suppl.9016

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

9016

引用

页数：3